TABLE 3.
Association of Medication Regimen Synchronization With Adjuvant Endocrine Therapy Adherence
| Odds Ratioa | 99% CI | |
|---|---|---|
| Medication-adjusted synchronization quartiles | ||
| 1 | 1 | Reference |
| 2 | 1.22 | 0.97–1.53 |
| 3 | 1.30 | 1.05–1.60 |
| 4 | 1.49 | 1.19–1.87 |
| Age | ||
| 66–70 y | 1 | Reference |
| 71–75 y | 0.93 | 0.75–1.16 |
| 76–80 y | 0.85 | 0.68–1.07 |
| 81–85 y | 0.75 | 0.59–0.97 |
| 86–90 y | 0.80 | 0.57–1.14 |
| Race (SEER) | ||
| White | 1 | Reference |
| Black | 0.99 | 0.71–1.39 |
| Other | 1.84 | 1.16–2.92 |
| Unknown | 0.75 | 0.28–2.06 |
| Low-income subsidy (including dual eligibility for Medicare and Medicaid) | 1.06 | 0.87–1.29 |
| Comorbidity (≥1) | 0.82 | 0.69–0.96 |
| Stage | ||
| 0 | 1 | Reference |
| I | 1.00 | 0.72–1.38 |
| II | 1.21 | 0.86–1.72 |
| III | 0.96 | 0.63–1.46 |
| Unknown | 0.78 | 0.43–1.40 |
| Tamoxifen use (vs aromatase inhibitor) | 0.87 | 0.70–1.10 |
| Rural/urban county | ||
| Metropolitan area, >1 million | 1 | Reference |
| Metropolitan area, <1 million | 0.76 | 0.62–0.94 |
| Micropolitan (urban cluster of 10,000–49,999) | 1.07 | 0.73–1.55 |
| Rural | 1.13 | 0.83–1.52 |
Abbreviations: CI, confidence interval; SEER, Surveillance, Epidemiology, and End Results.
a
The odds ratios represent the odds of adherence, which is defined as possession of ≥80% of the expected medication as described in the text. Odds ratios have also been adjusted for the SEER site.
Prescription fill synchronization is strongly associated with adherence to endocrine therapy. Efforts to improve adherence should address poor prescription synchronization.
See also pages 000–000.